SCMP Sucampo Pharmaceuticals, Inc.

10.10
+0  (2%)
Previous Close 9.90
Open 9.85
Price To book 2.57
Market Cap 438.39M
Shares 43,405,000
Volume 594,453
Short Ratio 5.16
Av. Daily Volume 894,636

SEC filingsSee all SEC filings

  1. DEF 14A - Other definitive proxy statements 17775589
  2. 8-K - Current report 17732237
  3. 8-K - Current report 17684114
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17675123
  5. 8-K - Current report 17673873

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved April 23, 2013.
Amitiza/Lubiprostone
Opioid-induced bowel dysfunction
Cobiprostone development discontinued July 2016
Cobiprostone
Oral Mucositis
Phase 3 endpoint not met. Phase 3 trials to be initiated in mid 2017.
Lubiprostone
Pediatric functional constipation
Phase 2a trial did not meet endpoints
Cobiprostone
proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD)

Latest News

  1. Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference
  2. ETFs with exposure to Sucampo Pharmaceuticals, Inc. : April 26, 2017
  3. Sucampo Announces First Quarter 2017 Earnings Call
  4. New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1
  5. Sucampo (SCMP) Down 7.6% Since Earnings Report: Can It Rebound?
  6. 7 of the Worst-Performing Stocks in Gurus' Portfolios
  7. Sucampo just bought this local rare disease company for $200M
  8. Sucampo Acquires Vtesse Inc.
  9. Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare Conference
  10. Local drug company stocks react to Trump's proposed cuts to NIH, FDA
  11. Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual Healthcare Conference
  12. Sucampo Pharmaceuticals (SCMP): Moving Average Crossover Alert
  13. Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
  14. Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed
  15. Edited Transcript of SCMP earnings conference call or presentation 8-Mar-17 1:30pm GMT
  16. Here's Why Sucampo Pharmaceuticals Rose as Much as 13.3% Today
  17. Nasdaq Leads On Chips; Dow Dips As Caterpillar Off, Banks Up
  18. Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics
  19. Sucampo tops 4Q revenue forecasts